Last reviewed · How we verify

NCT06207006

E-intervention on Subclinical Fear of Cancer Recurrence

Recruiting now NA Last updated 3 October 2025
What this trial tests

NA trial testing eConquerFear-HK in Cancer in 48 participants. Currently enrolling.

Timeline
2 May 2024
Primary endpoint
30 December 2025
30 December 2025

Quick facts

Lead sponsorThe University of Hong Kong
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment48
Start date2 May 2024
Primary completion30 December 2025
Estimated completion30 December 2025
Sites1 location across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

The University of Hong Kong

Who can join

18 and older, any sex, with Cancer or Psychooncology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study aims to adapt a metacognition-based ConquerFear-HK to an internet-based self-management intervention, namely eConquerFear-HK and evaluate in a randomised controlled trial, its feasibility, utility, and potential effectiveness on fear of cancer recurrence reduction among local Chinese cancer survivors with subclinical fear of cancer recurrence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other The University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06207006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing